EUVIMEDEUVIMED entdecken
Systematische ÜbersichtMetaanalyse

L26/P-731 Serum Estradiol Levels and Reproductive Outcomes in Artificial Frozen Embryo Transfer Cycles: A Systematic Review and Meta-analysis

C. Maignien, M. Bourdon, V. Grzegorczyk-Martin, P. Di Pizio, C. Solignac, C. Nassar, S. Languille, P. Fauque, P. Santulli, M. Peigné

Human Reproduction · 01.07.2026 · 41 (Supplement_1)

DOI: 10.1093/humrep/deag083.1058 ↗

Kurz gefasst

Systematische Übersicht in der Zeitschrift Human Reproduction, online erschienen am 08.07.2026. Verfasst von C. Maignien und 9 weiteren Autor:innen.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Study question Are serum estradiol (E2) levels associated with reproductive outcomes in artificial frozen embryo transfer (FET) cycles ? Summary answer Higher serum E2 levels are inversely associated with live birth and clinical pregnancy rates in artificial FET cycles. What is known already E2 plays a central role in endometrial preparation and embryo implantation. In artificial FET cycles using hormonal replacement therapy (HRT), serum E2 concentrations vary widely depending on dosage, route of administration, and monitoring strategies, and may reach supraphysiological levels. While adequate E2 exposure is required for endometrial receptivity, excessive levels have been hypothesised to impair implantation and pregnancy outcomes. However, existing studies have reported inconsistent results, and no consensus exists regarding optimal serum E2 levels or thresholds associated with reproductive outcomes in artificial FET cycles. Study design, size, duration This was a systematic review and meta-analysis including 29 studies published from inception to July 31, 2025, comprising a total of 54,675 women undergoing artificial FET cycles. The primary outcome was live birth rate; secondary outcomes included clinical pregnancy, ongoing pregnancy, early pregnancy loss, and obstetrical outcomes. Participants/materials, setting, methods Studies assessing serum E2 levels and reproductive outcomes in artificial FET cycles were identified through PubMed, Embase, and the Cochrane Library. Two reviewers independently performed study selection, data extraction, and quality assessment using Newcastle–Ottawa, ROBINS-I, and ROB2 tools. Mean difference analyses, dose–response meta-analyses, and exploratory threshold analyses were conducted, with separate analyses for follicular and luteal phases and planned meta-regressions to explore potential confounders. Main results and the role of chance Twenty-nine studies were included, comprising one randomized controlled trial and 28 observational studies. Serum E2 levels during the follicular phase were reported in 23 studies (n = 48,725 women) and during the luteal phase in 10 studies (n = 5,950 women). Oral E2 administration was the most commonly used route. Pooled mean E2 levels did not differ significantly between women with and without live birth or clinical pregnancy in either phase. However, dose–response meta-analyses demonstrated a statistically significant inverse association between increasing serum E2 levels and both live birth and clinical pregnancy rates (all p < 0.001). In the follicular phase, each 100 pg/mL increase in E2 was associated with an approximately 3% relative reduction in live birth rate. Although no robust E2 threshold could be formally identified, exploratory analyses consistently suggested an inflection point around 300 pg/mL, above which live birth and clinical pregnancy rates tended to decline. Data on ongoing pregnancy and obstetrical outcomes were limited and insufficient to draw firm conclusions. Limitations, reasons for caution Most included studies were observational and heterogeneous in E2 measurement timing, dosing regimens, and routes of administration. Residual confounding cannot be excluded, and data on obstetrical outcomes were limited. Wider implications of the findings These findings suggest that excessive E2 exposure may negatively impact reproductive outcomes in artificial FET cycles and support more individualized E2 supplementation strategies rather than aiming for high serum levels. Trial registration number Yes

Zitieren

APA

Maignien, C., Bourdon, M., Grzegorczyk-Martin, V., Pizio, P. D., Solignac, C., Nassar, C., Languille, S., Fauque, P., Santulli, P., & Peigné, M. (2026). L26/P-731 Serum Estradiol Levels and Reproductive Outcomes in Artificial Frozen Embryo Transfer Cycles: A Systematic Review and Meta-analysis. Human Reproduction, 41(Supplement_1). https://doi.org/10.1093/humrep/deag083.1058

Vancouver

Maignien C, Bourdon M, Grzegorczyk-Martin V, Pizio PD, Solignac C, Nassar C, et al. L26/P-731 Serum Estradiol Levels and Reproductive Outcomes in Artificial Frozen Embryo Transfer Cycles: A Systematic Review and Meta-analysis. Human Reproduction. 2026;41(Supplement_1). doi:10.1093/humrep/deag083.1058

BibTeX
@article{Maignien2026,
  author = {Maignien, C. and Bourdon, M. and Grzegorczyk-Martin, V. and Pizio, P. Di and Solignac, C. and Nassar, C. and Languille, S. and Fauque, P. and Santulli, P. and Peigné, M.},
  title = {L26/P-731 Serum Estradiol Levels and Reproductive Outcomes in Artificial Frozen Embryo Transfer Cycles: A Systematic Review and Meta-analysis},
  journal = {Human Reproduction},
  year = {2026},
  volume = {41},
  number = {Supplement_1},
  doi = {10.1093/humrep/deag083.1058}
}
Kostenlos starten →